Granules India Limited (NSE:GRANULES, BSE:532482) announced its unaudited consolidated financial results for the quarter ended June 30, 2026 on July 21, 2026. The company reported consolidated profit after tax (PAT) of INR 1,800 million, representing a year-on-year growth of 60%, while revenue from operations rose 22% YoY to INR 14,768 million. EBITDA increased 37% YoY to INR 3,389 million.
Key Highlights
- Q1FY27 revenue from operations reached INR 14,768 million, up 22% year-on-year from INR 12,101 million in Q1FY26.
- Profit after tax (PAT) stood at INR 1,800 million, a 60% increase year-on-year from INR 1,126 million in Q1FY26.
- EBITDA for the quarter was INR 3,389 million, representing 37% growth year-on-year, with EBITDA margin at 23%.
- North America revenue contribution decreased to 72% in Q1FY27 from 77% in Q1FY26, while Europe revenue contribution increased to 16% from 13%.
- Net debt decreased significantly to INR 1,012 million from INR 9,479 million in Q1FY26, with net debt-to-EBITDA ratio at 0.07x.
- Return on capital employed (ROCE) improved to 18.0% in Q1FY27 from 17.6% in FY26.
- Finished dosages, APIs, pharmaceutical formulation intermediates, and peptides CDMO contributed 74%, 13%, 9%, and 4% of revenue respectively.
About the Company
Granules India Limited, incorporated in 1991 and listed on the National Stock Exchange (NSE:GRANULES) and BSE (532482), is a vertically integrated pharmaceutical company headquartered in Hyderabad, Telangana. The company operates across the entire pharmaceutical value chain, including Active Pharmaceutical Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs), Finished Dosages (FDs), and Peptides Contract Development and Manufacturing Organization (CDMO) services. Granules operates 10 manufacturing facilities across India, USA, and Switzerland, and distributes products to over 300 customers across regulated and semi-regulated markets in more than 80 countries. The company holds regulatory approvals from US FDA, EDQM, EU GMP, COFEPRIS, WHO GMP, TGA, Korea FDA, DEA, MCC, and HALAL certification.
Announcement in Detail
Granules India released its Q1FY27 consolidated financial results for the quarter ended June 30, 2026. The company's revenue from operations reached INR 14,768 million in Q1FY27, representing marginal sequential growth of 0% compared to Q4FY26 (INR 14,706 million) but a strong year-on-year expansion of 22% from Q1FY26 (INR 12,101 million). EBITDA declined 4% sequentially to INR 3,389 million from INR 3,521 million in Q4FY26, but grew 37% year-on-year from INR 2,467 million in Q1FY26. EBITDA margin stood at 23% in Q1FY27 compared to 24% in Q4FY26 and 20% in Q1FY26.
Profit before tax (PBT) before exceptional items reached INR 2,404 million in Q1FY27, down 2% sequentially from INR 2,464 million in Q4FY26 but up 41% year-on-year from INR 1,704 million in Q1FY26. The quarter recorded no exceptional items. PAT for the quarter was INR 1,800 million, down 11% sequentially from INR 2,016 million in Q4FY26 but substantially up 60% year-on-year from INR 1,126 million in Q1FY26. PAT margin was 12% in Q1FY27 compared to 14% in Q4FY26 and 9% in Q1FY26. The company's net debt position improved significantly to INR 1,012 million at the end of Q1FY27, a reduction of INR 8,467 million compared to Q1FY26, with net debt-to-EBITDA at 0.07x.
Geographically, North America revenue contribution decreased to 72% of total revenue in Q1FY27 from 77% in Q1FY26, while Europe's contribution increased to 16% from 13%. By business segment, finished dosages accounted for 74% of revenue, APIs contributed 13%, pharmaceutical formulation intermediates represented 9%, and peptides CDMO services contributed 4% in Q1FY27. Return on capital employed improved to 18.0% in Q1FY27 from 17.6% in the full year FY26.
Impact on Investors
The Q1FY27 results demonstrate strong year-on-year profitability growth, with PAT expanding 60% to INR 1,800 million despite sequential quarterly decline. Investors will note that the year-on-year growth trajectory in EBITDA (37% increase) and PBT before exceptional items (41% increase) significantly outpaced revenue growth (22% increase), indicating improved operational leverage and margin expansion. The PAT margin expansion to 12% from 9% year-on-year reflects the company's ability to convert higher revenues into proportionally greater bottom-line earnings. The consolidated quarterly performance shows the company is translating its strategic investments during FY26 into execution confidence and business resilience as stated by management.
The substantial improvement in the net debt position to INR 1,012 million from INR 9,479 million in Q1FY26 is a significant positive for shareholders, representing deleveraging of INR 8,467 million within twelve months. The net debt-to-EBITDA ratio of 0.07x indicates conservative leverage and increased financial flexibility. The ROCE improvement to 18.0% from 17.6% signals enhanced capital efficiency. Shareholders will observe that the geographic diversification efforts, with Europe's revenue contribution increasing from 13% to 16% while North America maintained 72% of revenues, reflect progress toward the stated strategic objective of geographic and customer diversification. The segment mix showing finished dosages at 74% and growing contributions from higher-margin segments like peptides CDMO services underscores the portfolio transformation toward more complex and differentiated products.
Sector / Market Context
The Indian pharmaceutical industry continues to expand its global footprint with a focus on complex generics, specialty pharmaceuticals, and contract manufacturing services. India's pharmaceutical exports have been growing steadily, with North America and Europe representing the largest markets for Indian drugmakers. The global peptides and CDMO market has seen increased demand from biotechnology and specialty pharmaceutical companies seeking manufacturing outsourcing partners with regulatory expertise. Within the pharmaceutical industry, companies demonstrating geographic diversification and vertical integration across the value chain have been positioned to benefit from evolving global supply chain dynamics and customer preferences for single-source manufacturing partners. Granules' multi-facility presence across India, USA, and Switzerland aligns with global pharmaceutical companies' strategy to de-risk their supply chains through geographic distribution and regulatory access across multiple jurisdictions.